GE HealthCare enters an agreement to distribute Flyrcado through CDL Nuclear Technologies Group, a leading provider of cardiac PET imaging equipment and services in the U.S.

United States, Sept. 8 -- GE HealthCare announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado (TM) (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.Around six million myocardial perfusion imaging (MPI) procedures are performed each year in the U.S. Wi...